126 related articles for article (PubMed ID: 34802103)
1. ASO Author Reflections: An Evolving Skeletal Muscle Profiling-Towards Precise Host Phenotype and Prognostic Stratification in Non-small Cell Lung Cancer.
Sun C; Anraku M; Nakajima J
Ann Surg Oncol; 2022 Mar; 29(3):1825-1826. PubMed ID: 34802103
[No Abstract] [Full Text] [Related]
2. ASO Author Reflections: The Possibility of a New Prognostic Biomarker of Pericardial Fat Volumes in Resected Non-small Cell Lung Cancer.
Shinohara S; Kobayashi K; Nakagawa M
Ann Surg Oncol; 2020 Feb; 27(2):490-491. PubMed ID: 31659635
[No Abstract] [Full Text] [Related]
3. ASO Author Reflections: Key Components of the Hedgehog Signaling Pathway as Prognostic Biomarkers in Non-small Cell Lung Cancer.
Herreros-Pomares A; Jantus-Lewintre E
Ann Surg Oncol; 2023 Feb; 30(2):1236-1237. PubMed ID: 36125572
[No Abstract] [Full Text] [Related]
4. ASO Author Reflections: Clinical Significance of Combined Plasma Fibrinogen Level and Neutrophil-to-Lymphocyte Ratio in Non-small Cell Lung Cancer.
Iwasaki M; Ishihara S; Inoue M
Ann Surg Oncol; 2022 Sep; 29(9):5708-5709. PubMed ID: 35614370
[No Abstract] [Full Text] [Related]
5. ASO Author Reflections: Which of Smoking Duration or Smoking Intensity Contributes to Poor Prognosis After Resection of Non-small Cell Lung Cancer?
Takamori S; Okamoto T; Mori M
Ann Surg Oncol; 2020 Dec; 27(Suppl 3):834-835. PubMed ID: 32642994
[No Abstract] [Full Text] [Related]
6. ASO Author Reflections: The C-Reactive Protein (CRP)-Albumin Ratio May Be Useful as the Most Prognostic Index Among the Immuno-nutritional Parameters Using CRP and Albumin for Resected NSCLC.
Matsubara T; Okamoto T
Ann Surg Oncol; 2021 Jun; 28(6):3055-3056. PubMed ID: 33095364
[No Abstract] [Full Text] [Related]
7. ASO Author Reflections: Survival Impact of N2 in Non-small Cell Lung Cancer.
Clément-Duchêne C
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):944-945. PubMed ID: 30244416
[No Abstract] [Full Text] [Related]
8. ASO Author Reflections: Prognostic Nutritional Index-Based Risk Stratification for Lung Cancer.
Okada S; Inoue M
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):954-955. PubMed ID: 30306371
[No Abstract] [Full Text] [Related]
9. ASO Author Reflections: High Stromal TGFBI is a Useful Predictive Marker for Nivolumab in Non-small Cell Lung Cancer.
Nakazawa N; Yokobori T; Turtoi A; Shirabe K
Ann Surg Oncol; 2020 Mar; 27(3):943-944. PubMed ID: 31696394
[No Abstract] [Full Text] [Related]
10. ASO Author Reflections: Comprehensive Comparison of N Staging Subclassification Methods for Non-Small-Cell Lung Cancer.
Yang Z; Wang Z; Liu L
Ann Surg Oncol; 2022 Dec; 29(13):8154-8155. PubMed ID: 35989395
[No Abstract] [Full Text] [Related]
11. ASO Author Reflections: TNM 8th Edition: Stage I Non-small Cell Lung Cancer-Free from Recurrence and Adjuvant Therapy? How to Predict?
Zeng Y; Mayne N; Yang CJ; Liang W; He J
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):745-746. PubMed ID: 31555939
[No Abstract] [Full Text] [Related]
12. ASO Author Reflections: The Dissection of Station 4L Lymph Node for Left-Sided Non-Small Cell Lung Cancer Should Receive More Attention.
Liu L; Zhang Z
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):705-706. PubMed ID: 31463697
[No Abstract] [Full Text] [Related]
13. ASO Author Reflections: Sublobar Resection En Route to Becoming the Standard of Care for cT1N0 Lung Adenocarcinoma.
Lin MW; Chen JS
Ann Surg Oncol; 2020 Mar; 27(3):716-717. PubMed ID: 31667722
[No Abstract] [Full Text] [Related]
14. ASO Author Reflections: Spread Through Air Spaces in Margin of Sublobar Resection.
Ren Y; Xie H; Dai C; Chen C
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):682-683. PubMed ID: 31396781
[No Abstract] [Full Text] [Related]
15. Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer.
Sjøblom B; Grønberg BH; Wentzel-Larsen T; Baracos VE; Hjermstad MJ; Aass N; Bremnes RM; Fløtten Ø; Bye A; Jordhøy M
Clin Nutr; 2016 Dec; 35(6):1386-1393. PubMed ID: 27102408
[TBL] [Abstract][Full Text] [Related]
16. ASO Author Reflections: Proposed Nodal Categories for Future Editions of the TNM Classification of Non-small Cell Lung Cancer.
Li S; Wu N
Ann Surg Oncol; 2021 Aug; 28(8):4517-4518. PubMed ID: 33423120
[No Abstract] [Full Text] [Related]
17. Combination of Skeletal Muscle Mass and Density Predicts Postoperative Complications and Survival of Patients With Non-Small Cell Lung Cancer.
Sun C; Anraku M; Kawahara T; Karasaki T; Konoeda C; Kitano K; Sato M; Nakajima J
Ann Surg Oncol; 2022 Mar; 29(3):1816-1824. PubMed ID: 34997412
[TBL] [Abstract][Full Text] [Related]
18. ASO Author Reflections: Could VAMLA be a Therapeutic Strategy in Selected Patients with Left-sided NSCLC?
Yun JK; Kim YH
Ann Surg Oncol; 2022 May; 29(5):2840-2841. PubMed ID: 34994894
[No Abstract] [Full Text] [Related]
19. ASO Author Reflections: Impact of the Postoperative Neutrophil-to-Lymphocyte Ratio in Locally Advanced Non-small Cell Lung Cancer Treated with Induction Chemoradiotherapy Followed by Surgery.
Tsudaka S; Yamamoto H; Sato H; Toyooka S
Ann Surg Oncol; 2021 Sep; 28(9):4891-4892. PubMed ID: 33634386
[No Abstract] [Full Text] [Related]
20. ASO Author Reflections: Old Song, New Sung-Extracapsular Extension in Lung Cancer in the Era of Eighth-Edition N Classification.
Chen D; Ding Q; Wang W; Chen C; Chen Y
Ann Surg Oncol; 2021 Apr; 28(4):2099-2100. PubMed ID: 32960391
[No Abstract] [Full Text] [Related]
[Next] [New Search]
